Drug Safety

, Volume 36, Issue 2, pp 83–91 | Cite as

Malaria Prophylaxis in Patients with Renal Impairment

A Review
  • Sabine Amet
  • Sarah Zimner-Rapuch
  • Vincent Launay-Vacher
  • Nicolas Janus
  • Gilbert Deray
Practical Application

Abstract

Malaria is an endemic and potentially lethal disease transmitted by the protozoan parasite Plasmodium. It is currently endemic in more than 100 countries, which are visited by 125 million international travellers every year. For dialysis and renal insufficiency patients it becomes increasingly easier to travel to these countries thanks to the recent advances in renal replacement therapy. However, the pharmacokinetics of some prophylactic agents in malaria are altered, which may modify the effectiveness and safety of such treatments and the way they should be prescribed. Clinicians should be aware of these alterations which require subsequent dosage adjustments. This review provides recommendations on the use of antimalarial drugs, alone or in combination, in patients with renal impairment. These recommendations depend on the prevalence of Plasmodium falciparum chloroquine resistance, as defined by the WHO. Furthermore, fixed-dose combinations cannot be used in patients with creatinine clearance below 60 mL/min since the tablets available do not allow appropriate dosage adjustment for each drug. Chloroquine and proguanil require dosage adjustments, while atovaquone, doxycycline and mefloquine do not.

Notes

Acknowledgements

Native English editing and manuscript styling was provided by Andrea Bothwell of inScience Communications, a Wolters Kluwer business, with funding by Astellas.

The authors have no conflicts of interest to declare that are directly relevant to this article.

References

  1. 1.
    Garcia LS. Malaria. Clin Lab Med. 2010;30(1):93–129.PubMedCrossRefGoogle Scholar
  2. 2.
    Kihara M, Carter JA, Newton CR. The effect of Plasmodium falciparum on cognition: a systematic review. Trop Med Int Health. 2006;11(4):386–97.PubMedCrossRefGoogle Scholar
  3. 3.
  4. 4.
    Rossi I, Dacremont V, Peytremann-Bridevaux I. Prevention of malaria in travellers: which antimalarial is best? Rev Med Suisse. 2010;6:1840.PubMedGoogle Scholar
  5. 5.
    Field V, Gautret P, Schlagenhauf P, et al. Travel and migration associated infectious diseases morbidity in Europe, 2008. BMC Infect Dis. 2010;10:330.PubMedCrossRefGoogle Scholar
  6. 6.
    WHO. Malaria. In: International travel and health 2010. Geneva: WHO, 2010. http://www.who.int/ith/ITH2010chapter7.pdf. Accessed 27 Dec 2012.
  7. 7.
    Fernando SD, Rodrigo C, Rajapakse S. The ‘hidden’ burden of malaria: cognitive impairment following infection. Malar J. 2010;9:366.PubMedCrossRefGoogle Scholar
  8. 8.
    Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.PubMedCrossRefGoogle Scholar
  9. 9.
    Launay-Vacher V, Spano JP, Janus N, et al. Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol. 2009;70:124–33.PubMedCrossRefGoogle Scholar
  10. 10.
    Karie S, Launay-Vacher V, Deray G. GPR: antibiotiques et antifongiques. 3rd edition. Guide de prescription des médicaments chez le patient insuffisant rénal. Paris: Meditions International; 2008.Google Scholar
  11. 11.
    Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298(17):2038–47.PubMedCrossRefGoogle Scholar
  12. 12.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.PubMedCrossRefGoogle Scholar
  13. 13.
    Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Froissart M, Rossert J, Jacquot C, et al. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005;16:763–73.PubMedCrossRefGoogle Scholar
  15. 15.
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266.CrossRefGoogle Scholar
  16. 16.
    Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005;67:2089–100.PubMedCrossRefGoogle Scholar
  17. 17.
    Stevens LA, Levey AS. Use of the MDRD study equation to estimate kidney function for drug dosing. Clin Pharmacol Ther. 2009;86(5):465–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Verbeeck RK, Musuamba FT. Pharmacokinetics and dosage adjustment in patients with renal dysfunction. Eur J Clin Pharmacol. 2009;65(8):757–77.PubMedCrossRefGoogle Scholar
  19. 19.
    Launay-Vacher V, Storme T, Izzedine H, et al. Pharmacokinetic changes in renal failure. Presse Med. 2001;30(12):597–604.PubMedGoogle Scholar
  20. 20.
    Thorogood N, Atwal S, Mills W, et al. The risk of antimalarials in patients with renal failure. Postgrad Med J. 2007;83(986):e8.PubMedCrossRefGoogle Scholar
  21. 21.
    Summary of product characteristics (SmPC) of Nivaquine® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0130632.htm. Accessed 8 Aug 2012.
  22. 22.
    Stahel E, Druilhe P, Gentilini M. Antagonism of chloroquine with other antimalarials. Trans R Soc Trop Med Hyg. 1988;82(2):221.PubMedCrossRefGoogle Scholar
  23. 23.
    White NJ. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985;10:187–215.PubMedCrossRefGoogle Scholar
  24. 24.
    Salako LA, Walker O, Iyun AO. Pharmacokinetics of chloroquine in renal insufficiency. Afr J Med Med Sci. 1984;13(3–4):177–82.PubMedGoogle Scholar
  25. 25.
    Akintonwa A, Odutola TA, Edeki T, et al. Hemodialysis clearance of chloroquine in uremic patients. Ther Drug Monit. 1986;8(3):285–7.PubMedCrossRefGoogle Scholar
  26. 26.
    Launay-Vacher V, Izzedine H, Baumelou A, et al. FHD: an index to evaluate drug elimination by hemodialysis. Am J Nephrol. 2005;25:342–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Chiluba EM, Fletcher KA, Price AH. The pharmacokinetics of proguanil in human subjects following a single oral dose. Afr J Med Med Sci. 1987;16(1):43–6.PubMedGoogle Scholar
  28. 28.
    Tattersall JE, Greenwood RN, Baker LR, et al. Proguanil poisoning in a hemodialysis patient. Clin Nephrol. 1987;28(2):104.PubMedGoogle Scholar
  29. 29.
    Boots M, Phillips M, Curtis JR. Megaloblastic anemia and pancytopenia due to proguanil in patients with chronic renal failure. Clin Nephrol. 1982;18(2):106–8.PubMedGoogle Scholar
  30. 30.
    Sirsat RA, Dasgupta A. Haematological complications of proguanil in a patient with chronic renal failure. Nephron. 1997;75(1):108.PubMedCrossRefGoogle Scholar
  31. 31.
    Summary of product characteristics (SmPC) of Paludrine® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0207917.htm. Accessed 8 Aug 2012.
  32. 32.
    Summary of product characteristics (SmPC) of Savarine® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0167697.htm. Accessed 8 Aug 2012.
  33. 33.
    Summary of product characteristics (SmPC) of Malarone® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0173830.htm. Accessed 8 Aug 2012.
  34. 34.
    Rolan PE, Mercer AJ, Tate E, et al. Disposition of atovaquone in humans. Antimicrob Agents Chemother. 1997;41(6):1319–21.PubMedGoogle Scholar
  35. 35.
    Spencer CM, Goa KL. Atovaquone: a review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs. 1995;50(1):176–96.PubMedCrossRefGoogle Scholar
  36. 36.
    Hughes WT, Kennedy W, Shenep JL, et al. Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men. J Infect Dis. 1991;163(4):843–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Aronoff GR, Bennett WM, Berns JS, et al. Drug prescribing in renal failure: dosing guidelines for adults and children. 5th ed. Philadelphia: American College of Physicians; 2007.Google Scholar
  38. 38.
    Jolink H, den Hartigh J, Visser LG, et al. Pancytopenia due to proguanil toxicity in a returning traveller with fever. Eur J Clin Pharmacol. 2010;66(8):811–2.PubMedCrossRefGoogle Scholar
  39. 39.
    Summary of product characteristics (SmPC) of Lariam® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0201777.htm. Accessed 8 Aug 2012.
  40. 40.
    Development of mefloquine as an antimalarial drug. Bull World Health Organ. 1983;61(2):169–178.Google Scholar
  41. 41.
    Launay-Vacher V, Bassilios N, Deray G. GPR: antifongiques et antiparasitaires. Guide de prescription des médicaments chez le patient insuffisant rénal. Paris: Méditions International; 2002.Google Scholar
  42. 42.
    Crevoisier CA, Joseph I, Fischer M, et al. Influence of hemodialysis on plasma concentration-time profiles of mefloquine in two patients with end-stage renal disease: a prophylactic monitoring study. Antimicrob Agents Chemother. 1995;39(8):1892–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Desjardins RE, Canfield CJ, Haynes JD, et al. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother. 1979;16(6):710–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Palmer KJ, Holliday SM, Brogden RN. Mefloquine: a review of its antimalarial activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1993;45(3):430–75.PubMedCrossRefGoogle Scholar
  45. 45.
    Summary of product characteristics (SmPC) of Vibramycin® [in French]. http://agence-prd.ansm.sante.fr/php/ecodex/rcp/R0173656.htm. Accessed 8 Aug 2012.
  46. 46.
    Bassilios N, Launay-Vacher V, Deray G. GPR: antibactériens. Guide de prescription des médicaments chez le patient insuffisant rénal. Paris: Méditions International; 2002.Google Scholar
  47. 47.
    Fabre J, Milek EF, Kalfopoulos P, et al. Tetracycline kinetics in man: digestive absorption and serum concentration. Schweiz Med Wochenschr. 1971;101(17):593–8.PubMedGoogle Scholar
  48. 48.
    Whelton A, Schach von Wittenau M, Twomey TM. Doxycycline pharmacokinetics in the absence of renal function. Kidney Int. 1974;5(5):365–71.PubMedCrossRefGoogle Scholar
  49. 49.
    Ao NK, Taneja OP, Bhatia VN, et al. Serum concentration and urinary excretion of doxycycline in normal subjects and patients with renal insufficiency. Chemotherapy. 1974;20(3):129–40.PubMedCrossRefGoogle Scholar
  50. 50.
    Lee P, Crutch ER, Morrison RB. Doxycycline: studies in normal subjects and patients with renal failure. N Z Med J. 1972;75:355–8.PubMedGoogle Scholar
  51. 51.
    Barza M, Schiefe RT. Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part I: tetracyclines. Am J Hosp Pharm. 1977;34(1):49–57.PubMedGoogle Scholar
  52. 52.
    Houin G, Brunner F, Nebout T, et al. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br J Clin Pharmacol. 1983;16(3):245–52.PubMedCrossRefGoogle Scholar
  53. 53.
    Jaffe JM, Colaizzi JL, Poust RI, et al. Effect of altered urinary pH on tetracycline and doxycycline excretion in humans. J Pharmacokinet Biopharm. 1973;1(4):267–82.CrossRefGoogle Scholar
  54. 54.
    Shmuklarsky MJ, Boudreau EF, Pang LW, et al. Failure of doxycycline as a causal prophylactic agents against Plasmodium falciparum malaria in healthy non immune volunteers. Ann Intern Med. 1994;120(4):294–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Institut de veille Sanitaire. Health recommendations for travellers, 2012. Bulletin épidémiologique hebdomadaire no 20–21, 2012. http://www.invs.sante.fr/Publications-et-outils/BEH-Bulletin-epidemiologique-hebdomadaire/Derniers-numeros-et-archives/Archives/2012/BEH-n-20-21-20122. Accessed 27 Dec 2012.
  56. 56.
    Centers for Disease Control and Prevention. Malaria information and prophylaxis, by country. http://www.cdc.gov/malaria/travelers/country_table/t.html. Accessed 14 Jan 2013.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Sabine Amet
    • 1
  • Sarah Zimner-Rapuch
    • 1
  • Vincent Launay-Vacher
    • 1
  • Nicolas Janus
    • 1
  • Gilbert Deray
    • 2
  1. 1.Service ICAR Department, Nephrology DepartmentPitié-Salpêtrière HospitalParisFrance
  2. 2.Nephrology DepartmentPitié-Salpêtrière HospitalParisFrance

Personalised recommendations